https://www.cellectar.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_82fb76d941e714ade0a9b4bd7ead767d/cellectar/files/theme/images/logo-sm.png /investors Equisolve Investor Relations Suite https://www.cellectar.com/investors/news-events/press-releases/detail/392/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates Thu, 14 May 26 07:15:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/392/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates https://www.cellectar.com/investors/news-events/press-releases/detail/391/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026 Mon, 11 May 26 08:05:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/391/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026 https://www.cellectar.com/investors/news-events/press-releases/detail/390/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-rr-waldenstrm-macroglobulinemia Tue, 05 May 26 07:10:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/390/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-rr-waldenstrm-macroglobulinemia https://www.cellectar.com/investors/news-events/press-releases/detail/389/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Tue, 05 May 26 07:00:00 -0400 https://www.cellectar.com/investors/news-events/press-releases/detail/389/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million